Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Literature
1.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732–46.CrossRefPubMed
2.
Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol. 2015;19:1044–53.CrossRefPubMed
3.
Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18:876–84.CrossRefPubMedPubMedCentral
4.
Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, et al. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice. Eur J Pharmacol. 2016;780:224–31.CrossRefPubMed
5.
Sakuma S, Fujita J, Nakanishi M, Wada S, Fujimoto Y. Disulfide s-monoxides convert xanthine dehydrogenase into oxidase in rat liver cytosol more potently than their respective disulfides. Biol Pharm Bull 2008;31:1013–1016.CrossRefPubMed
Metadata
Title
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion
Authors
Hiroyuki Terawaki
Hokuto Hoshi
Junichiro James Kazama
Publication date
01-04-2017
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1388-7

Other articles of this Issue 2/2017

Clinical and Experimental Nephrology 2/2017 Go to the issue

Original Article

Cardiac troponin T elevation at dialysis initiation is associated with all-cause and cardiovascular mortality on dialysis in patients without diabetic nephropathy

Original Article

Efficacy of low-density lipoprotein apheresis combined with corticosteroids for cholesterol crystal embolism

Original article

A clinical staging score to measure the severity of dialysis-related amyloidosis

Review article

Time to target uric acid to retard CKD progression

Original article

Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells

Original Article

Feasibility of intermittent back-filtrate infusion hemodiafiltration to reduce intradialytic hypotension in patients with cardiovascular instability: a pilot study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits